Evidence · Randomised trial
rhIGF-1/rhIGFBP-3 in Preterm Infants: A Phase 2 Randomized Controlled Trial.
- Bronchopulmonary dysplasia
- Eyes and hearing
- Growth
- Intraventricular haemorrhage and white matter injury
- Medical
- Neurology
- Nutrition and gastrointestinal
- Respiratory
- Retinopathy of prematurity
This paper is from 2019, more than five years ago. Newer evidence may have been published since.
Summary
Phase 2 randomised controlled trial in extremely preterm infants (23 to 27 weeks' gestation) comparing continuous intravenous rhIGF-1/rhIGFBP-3 with standard neonatal care. The primary outcome was maximum severity of retinopathy of prematurity, with secondary outcomes including bronchopulmonary dysplasia, intraventricular haemorrhage, growth and time to discharge. Treatment did not reduce ROP but was associated with fewer cases of severe BPD and a non-significant trend towards less severe IVH. Fatal serious adverse events were numerically more frequent in the treated group, and many treated infants did not achieve target exposure.
Summary written for NICUlearn. Always read the original.
- Licence:
- Open (Creative Commons)
The full text of this openly licensed paper is available to NICUlearn members, and Neeky can answer questions from it.
Guidelines are shown for education. Follow your unit's own guidance and senior advice.